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ABSTRAK
Indonesia merupakan salah satu negara tropis dan agraris terbesar di dunia, yang berpotensi memiliki angka 
kasus gigitan ular yang tinggi namun seringkali tidak tercatat. Pada satu dekade terakhir ini, Badan Kesehatan 
Dunia (WHO) memasukkan kasus gigitan ular dalam daftar penyakit tropis yang terabaikan. Manifestasi klinis 
gigitan ular bervariasi bergantung kepada jenis bisa ular berupa gejala ringan hingga mengancam jiwa. 
Ketepatan pertolongan pertama, serta tatalaksana komprehensif dari setiap kasus gigitan ular diperlukan untuk 
mengurangi angka kematian dan kesakitan.
Kata kunci: gigitan ular, penyakit tropis terabaikan, Indonesia, tatalaksana, serum anti bisa ular.
ABSTRACT
Indonesia as one of the largest tropical and agricultural countries in the world shared the particularly 
high burden cases of snakebite. In the last decade, World Health Organization (WHO) has listed snakebite as 
one of the neglected tropical disease. The clinical manifestations of snakebite could vary according to the type 
of venoms ranging from mild to life threatening condition. Appropriate first aid treatment and comprehensive 
management of snakebite cases are warranted to reduce mortality and morbidity rates. 
Key words: snakebite, neglected tropical disease, Indonesia, treatment, antivenom.
INTRODUCTION
Indonesia as one of the largest tropical 
countries in the world had particularly high 
burden cases of snakebite. In addition, many 
Indonesians are working in agricultural field 
which is regarded as high risk population for 
snakebites.1 Other neighboring tropical countries 
in Southeast Asia region such as Malaysia, 
Thailand, and Myanmar also shared the same 
burden of disease.2 Despite that, government 
and public health community still shared little 
attention. At the present time in Indonesia, there 
was no national epidemiology report, lack of 
national policy on snakebite control program, 
and updated national guideline in snakebite 
management. Limited snakebite information 
reflects that the disease is still one of the 
neglected tropical disease in Indonesia. This 
review aims at summarizing the epidemiology, 
clinical manifestations, diagnosis, treatment, and 
prevention strategies of snakebite in Indonesia.
BURDEN OF DISEASE 
In 2009, WHO included snakebites in WHO 
list of neglected tropical diseases and even until 
now remains as a global public health problem. 
Katsusirane et al estimated about 1,200,000–
5,500,000 snakebites, 421,000-1,841,000 
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envenoming, and 20,000-94,000 deaths may 
occur globally per year, with South Asia and 
Southeast Asia have the highest burden. In 
Indonesia, there were 12,739–214,883 snakebite 
cases estimated with 20–11,581 deaths in 2007.2 
This estimation was mainly based on reported 
studies and may differ with the actual numbers. 
There were many factors affecting the accuracy 
of the reported events, such as many snakebite 
cases occurred in rural area, traditionally treated, 
or never managed to reach hospital. Therefore 
the actual problem of snakebite might be bigger 
than previously estimated.3-5
In Indonesia, no national epidemiological 
reports are available. Epidemiological data 
of snakebite cases are very few and derived 
only from hospital based report. In 1996-1998 
there were 180 snakebite cases reported in 
Hasan Sadikin Public Hospital, Bandung.6 
In Cipto Mangunkusumo National Referral 
Hospital, there were only forty-two snakebite 
cases treated between 2004 and 2009. Among 
them, 17 patients showed envenomation signs.7 
Meanwhile, accurate epidemiological data 
was required for physicians and health policy 
maker to educate high risk population, to better 
distribute antivenom, and to provide prevention 
control program;8 while with no accurate data, 
morbidity and mortality will remain unavoidably 
high.
DISTRIBUTION OF VENOMOUS SNAKES IN 
INDONESIA
Worldwide, there are about 2,800 species 
of snakes, but only 320 species are medically 
important to human and classified into three 
families of venomous snakes, Atractaspididae, 
Elapidae, and Viperidae. Colubridae is the largest 
snake family considered to be harmless among 
most species, but some severe envenoming cases 
had been reported.9,10
In Indonesia, the distribution of snakebites 
can be divided into two groups based on 
biogeographical origins. The first group includes 
all snake species that have similarity with 
venomous snakes of Asian origin distributed 
in West of Wallace’s line (Sumatera, Java, 
Kalimantan, Sulawesi, and the lesser Sunda 
Island). While the second group has more 
similarity with Australo-Papuan region. This 
region includes East of Wallace’s line (West 
Papua and Maluku).11,12
WHO divided snake species into two 
categories based on its medical importance. 
The first category includes all highly venomous 
snakes with the highest medical importance, 
widely spread, and causing high level of 
mortality and morbidity. The second category 
includes venomous snakes which is defined as 
having secondary medical importance.12
Category I of Indonesian venomous snakes 
distributed in West of Wallace’s line consists 
of Elapidae and Viperidae families. The family 
Elapidae is represented by Bungarus candidus, 
Naja sputatrix, and Naja sumatrana.12 Bungarus 
candidus, also known as Malayan krait/Ular 
Weling, is a nocturnal snake that usually bites at 
night especially in rural area.13,14 Ular Weling is 
famous for its lethal dose neurotoxicity (LD50) 
3.5 µg per mouse which makes them one of the 
most toxic snakes.15 (Figure 1)
Figure 1. Bungarus candidus. (Courtesy of David Williams)
The Naja species is famous as Ular Kobra 
in local area and known for their spitting venom 
ability which is capable of causing venom 
opthalmia.13,16 Cobras can raise their head and 
spread their hood, as their defense mechanism.17 
(Figure 2)
Viperidae in WHO category 1 consist of 
Daboia siamensis, Cryptelytrops albolabris, 
and Calloselasma rhodostoma.12 Vipers have 
typically triangular head, laureal shields, and 
vertically elliptical pupils.18 Cryptelytrops 
albolabris/Ular hijau/White lipped pit viper live 
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in tropical forest and bamboo forest19 and can 
grow to 1.0 meter in length.
Daboia siamensis live in agricultural areas 
and hide behind the rock crevices and bushes. 
They are a slow moving nocturnal snake and hiss 
loudly but can strike fiercely when disturbed.20 
(Figure 3)
habitats, such as low and highland grass, 
rainforest, woodland, and savannah. In general, 
they have short body but can grow up to 1.0 meter 
in length. They tend to be motionless, but when 
touched they will strike rapidly.22 (Figure 4)
Figure 2. Naja sumatrana. (Courtesy of David Williams)
Figure 3. Daboia siamensis. (Courtesy of David Williams)
Calloselasma rhodostoma/Ular Tanah/Ular 
Biludak is a thick bodied snake that can grow 
about 1.10 meter in length, with triangular head. 
This snake is commonly found in lowland forest. 
Ular tanah is not an aggressive snake.21
In East of Wallace’s line, West Papua and 
Maluku, the only category I snake is Acanthopis 
laevis.12 This Elapidae snake is also known 
as Eastern Death Adder. They live in various 
Figure 4. Acanthopis laevis. (Courtesy of David Williams)
CLINICAL MANIFESTATIONS
The clinical manifestations may vary 
between bites, depending on the type of venom. 
Envenomings can manifest as local and fatal 
systemic symptoms, the severity depends on the 
location of the bite and the amount of venom 
injected. Pit viper snakebites can produce local 
manifestation as a local pain, swelling, and local 
skin necrosis, which in turn can lead to tissue loss 
and the patient may need to be amputated.23 The 
effect of cytotoxic and myotoxic of the venom 
can lead to rhabdomyolisis and in the end lead 
to acute renal failure.4 Crotaline venom mainly 
damaged the endothelial cell, causing plasma 
leakage and may lead to hypovolemic shock.24
Cobra, Kraits (Bungarus spp.), and sea 
snakes are known for their neurotoxicity 
feature.25 Neurotoxin can exert effect at pre-
synapse and post-synapse. Pre-synaptic toxins 
such as beta-bungarotoxin (b-BuTX) lead 
to degeneration of motor nerve, depletion of 
synaptic vessels, and destruction of motor nerve 
terminals; while post-synaptic neurotoxins such 
as alpha-neurotoxins bind to the acetylcholine 
receptor and lead to neuromuscular blockade.26 
The cranial nerves are usually affected first. 
Acute neuromuscular paralysis such as ptosis, 
facial weakness, paralysis, and respiratory 
muscle weakness are commonly reported.27
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Bleeding manifestations are reported for 
Rhabdophis snakebite and Crotaline. The fatal 
case is reported as bilateral acute epidural 
hemorrhage and subcortical hemorrhage with 
cerebral herniation.28 Other manifestations 
are ecchymosis, hematemesis, melena, and 
hematuria.24 This bleeding manifestations are 
mainly caused by venom induce consumption 
coagulopathy (VICC) and thrombocytopenia.29,30 
VICC occurred because of serine protease 
and procoagulant enzyme acting as factor V 
activators, factor X activators, prothrombin 
activators, and thrombin-like enzymes (TLEs), 
leading to vicious cycle which involved fibrin 
formation and degradation by plasmin, which 
in turn resulting depletion of coagulation 
factor.12,29,31
DIAGNOSIS
Snakebite is basically a clinical diagnosis 
and confirmed a history of bites by the patient 
or family or a witness. Four important questions 
should be asked when evaluating the patient: the 
location of the bite, the time patient got bitten, the 
characteristics of the snake, and the symptom.9,24 
Identification of snake species should be done 
even though sometimes it can be difficult by 
anamnesis alone. Venomous snakes are usually 
characterized by triangular heads, heat sensing 
pits, elliptical pupils, single row of subcaudal 
scales, and has typical bite mark with only one 
or two fangs punctures on the skin. Whereas non 
venomous snakes are characterized by round 
head, round pupil, double row of ventral scales, 
and the bite mark display small punctures in 
rows.32,33
Physical examination should be focused 
on vital sign, bleeding manifestation, bite site 
including bite marks, bruising, and draining 
lymph nodes. Neurological examination must 
be performed including cranial nerves, motor, 
and sensory examination.26
Required laboratory investigations are 
generally complete blood count, electrolyte, 
creatinine, BUN, clotting time, bleeding time, 
prothrombin time, aPTT, fibrinogen level, 
D-dimer, AST, ALT, creatine kinase, and blood 
type.10,34
SEARO recommends a 20-minute whole 
blood clotting test (20WBCT). The 20WBCT 
is a useful test for developing countries such as 
Indonesia, because snakebites can occur in rural 
areas where primary health care facility do not 
have capability to perform extensive clotting 
test. This test can be done on bedside and yield 
fast result. The test was done by pouring 2 mL of 
fresh venous blood in a dry glass vessel, and left 
it for 20 minutes. If the blood is still unclotted 
then the patient may have VICC. It can be used 
as a clue for viper bite and rules out elapid bite, 
also monitoring the effect of antivenom in terms 
of VICC treatment.12
Other routine tests that should be done are 
ECG and urinalysis to check for glucosuria, 
proteinuria, and myoglobinuria.12
SNAKEBITE MANAGEMENT
Management of  snakebite  requires 
comprehensive and collaborative approaches 
from pre hospital to advanced management in 
hospital. Even though there are already many 
published guidelines, the implementation is quite 
hard especially in rural area. Delay in patient 
transport, improper first aid management, initial 
visit to traditional healer, and limited antivenom 
supply are some of the factors to the worsening 
of poor clinical outcome.35-37 In Indonesia, 
available guideline on snakebite management 
was published by Sentra Informasi Keracunan 
Nasional Badan POM.38
First Aid
Proper first aid management became clinically 
important to be done, as it affected the outcome of 
patients.39 First aid management should be given 
as soon as possible by the nearby person with 
proper procedure, followed by transportation 
to hospital, possibly along with the snake. One 
of the most well studied first aid procedure is 
pressure bandage with immobilization (PBI) 
recommended by Australian authorities. Elastic 
broad bandage (15 cm) is applied at the bite 
site and covering the whole limb with the same 
pressure for sprained ankle.34 The rationale of 
this technique is blocking lymphatic flow without 
compromising arterial or venous blood flow, 
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therefore can limit the venom spreading.40
Many traditional first aid managements 
should not be done anymore as it is potentially 
harmful. Making incisions, and rubbing at the 
site of the bite wound could promote venom 
absorption. Electric shock, applying harmful 
herbal remedy, tying tight tourniquet and sucking 
out venom with mouth are not recommended.9,41
In-hospital Management
Initial management at hospital following 
primary surveys is recommended by Advanced 
Trauma Life. Support guidance involves 
securing airway, breathing and circulation. Every 
patients needs to be observed for hemodynamic 
changes and signs of envenomation. Patients 
need to be reassured to decrease their anxiety, 
as the data show most of snakebites are caused 
by nonvenomous species and about half of 
venomous snakebites occurred with no venom 
released.33 Paracetamol and opioid could 
be given as pain reliever, while NSAID are 
generally not recommended because of bleeding 
risk. In vomiting patient, recovery position 
with head turned to one side should be done to 
prevent aspiration and the patient can be given 
chlorphromazine 25-50 mg.9 Routine tetanus 
prophylaxis is also recommended to be given 
for snakebite victims.38
Sentra Informasi Keracunan Nasional Badan 
POM recommends routine administration of 
antibiotic prophylaxis.38 A study in Taiwan 
found that gram negative bacteria, such as 
Morganella morganii, Aeromonas hydrophila 
and Enterococcus was the common pathogen 
responsible for wound infection following 
snakebite. They recommended the use of 
piperacillin/tazobactam, quinolone, second- or 
third-generation cephalosporin for empirical 
therapy.42 While, Garg et al43 found that Gram 
positive bacteria, such as Staphylococcus aureus 
was the most common pathogen, followed 
by Gram negative bacteria Escherichia coli. 
Ciprofloxacin was recommended as empiric 
therapy due to gram positive and negative 
coverage.
Antivenom
Antivenom is the only definite therapy 
in snake envenomation but there were some 
limitations in its usage such as hypersensitivity 
reaction and not readily available.9 According 
to SEARO guideline, indications for antivenom 
are hemostatic abnormality, neurotoxic signs, 
cardiovascular abnormalities, acute kidney 
injury, hemoglobinuria, myoglobinuria, local 
swelling more than half of the bitten limb within 
48 hours of the bite, rapid extension of swelling, 
and enlarged tender lymph node.12
Antivenom should be given immediately 
whenever clinically indicated, however this 
practice is not always visible to do because 
of the limited availability of antivenom and 
the difficulty to identify the snake.44 Delayed 
anti-venom administration was reported still 
successfully treating the envenomings, therefore 
antivenom should be given as long as indicated.45
In Indonesia, the only snake antivenom 
available was Biosave®, produced by Biofarma, 
which was made from Equine serum. Biosave® 
is a polyvalent antivenom and indicated 
for neurotoxin produced by Naja sputatrix, 
Bungarus fasciatus, and hematoxin produced 
by Agkistrodon rhodostoma. For the first dose, 
2 vial @5 ml was diluted with normal saline to 
achieve concentration of 2%, then infused with 
a rate of 40-80 drops per minute. Another dose 
could be given 6 hours later. If the envenoming 
symptoms still persist, antivenom could be given 
every 24 hours with the maximal dose of 80-100 
ml. Undiluted antivenom could be given by very 
slowly pushing intravenous. Allergic test must be 
done before administration and monitoring must 
be done during and post administration. This 
polyvalent was not effective to neutralize venoms 
produced by snake from East Indonesia such as 
Acanthopis antarticus, Xyuranus scuttelatus, 
Pseudechis papuanus, also Enhydrina cystsa, 
due to no cross-neutralization ability.12,46
In VICC patient, antivenom was the mainstay 
treatment. Antivenom would bind to toxin, make 
it inactive, and promote elimination. However, 
there were some cases where antivenom failed 
to give improvement in VICC and recurrent 
coagulopathy. Experts believed the failure of 
antivenom for VICC treatment was caused by 
the rapid toxin effect, as once the coagulation 
pathway activated it was irreversible. However, 
antivenom was still useful in these cases because 
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it bind to procoagulation toxin and give time for 
coagulation factor to recover. Therefore, in terms 
of VICC, antivenom should be administered 
early.29,47,48
In case of severe bleeding, the patient may 
need coagulation factor replacement, such 
as fresh frozen plasma, cryoprecipitate, or 
whole blood transfusion. A study conducted in 
Australia reported that administration of FFP 
after antivenom was given would help replenish 
coagulation factor.47,48 The use of heparin for 
VICC was not supported by sufficient evidence 
and controversial due to mixed result. Therefore, 
the use of heparin was not recommended by 
WHO.12
In management of neurotoxicity, early 
administration of antivenom was critical because 
antivenom was unable to neutralize after venom 
bind.26 Early intubation may be needed to secure 
the airway in patient with bulbar involvement.49 
Trial of cholinesterase may be useful and should 
be given whenever neurotoxic symptoms were 
evident. Since edrophonium was not available 
in Indonesia, a longer-acting neostigmine could 
be given intramuscularly 0.02 mg/kg for adult. 
Atropine could be given as premedication to 
minimize adverse effect from neostigmine 
administration.18,26,49,50
As reported, the mortality rate of snake bite 
inducing acute renal failure is 15% to 20%.51,52 
Therefore, evaluation of any acute renal failure 
signs such as oliguria, hematuria, proteinuria 
was important. So the patient can be treated 
earlier and referred to center with dialysis 
facility. Antivenom should be given early and 
renal replacement should be initiated as soon as 
indicated. Peritoneal dialysis was reported having 
the ability to reduce the mortality of acute renal 
failure following snake bite.53,54 Acidosis and 
hyperkalemia, should be treated accordingly. 
Furosemide challenge could be given to improve 
urine output. Sodium bicarbonate and mannitol 
could be used to prevent renal damage caused 
by myoglobinuria, however their use should be 
avoided in patient with established acute renal 
failure due to hyperosmolarity and hypervolemic 
effect.12,53
Early detection of compartment syndrome was 
important. Diagnosis could be made by combining 
intracompartmental pressure measurement and 
symptom based such as severe pain and pain 
with passive stretch. Antivenom should be 
administered, as it can reduce tissue pressures 
and myonecrosis. Fasciotomy was not the first 
line treatment, and only indicated if there was 
no improvement after antivenom administration. 
However, prophylactic fasciotomy were generally 
not recommended.12,55
PREVENTION
Prevention of snakebite becomes an 
important strategy to reduce the number of fatal 
or complicated cases. Prevention can be done by 
giving education to high risk population about 
local venomous snake species, snake’s habits, 
and some strategies to avoid snakebites. Some 
avoidance strategies are avoiding potential snake’s 
habitat such as tall grass, bushes, swamps, and 
holes in the ground; wearing loose, long pants, 
and boots especially for agricultural workers; 
using flashlight when walking during the night. 
However, in Indonesia all the information above 
might not be well distributed.12,56
CONCLUSION
Snakebite is a potentially important public 
health problem in Indonesia, but lacking detailed 
information on disease burden. Therefore health 
care providers are warranted to have knowledge in 
snake identification, proper first aid treatment, and 
case management in referral setting; as well as to 
involve the high-risk population in the prevention 
program.
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